GlassScriptPhysician profile
Christopher W Orendorff
NPI 1922233618
$12,363.44
in general payments reported to CMS, 2019-2025
38 companies · $1,899 in 2025
The $1,899 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $1,369 · 2021: $1,822 · 2022: $1,835 · 2023: $2,084 · 2024: $2,520 · 2025: $1,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,495 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,494.72 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,620.25 | 2021-2025 | |
| Novo Nordisk INC | $1,379.14 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,142.62 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Mylan Specialty L.P. | $989.59 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $663.59 | 2022-2025 | |
| Lilly USA, LLC | $639.33 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Sunovion Pharmaceuticals INC. | $631.12 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $574.43 | 2019-2023 | |
| Glaxosmithkline, LLC. | $480.11 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Supernus Pharmaceuticals, INC. | $428.88 | 2024 | Qelbree |
| Pfizer INC. | $428.83 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $414.01 | 2022-2025 | Caplyta |
| Amgen INC. | $393.35 | 2019-2023 | Repatha, Otezla |
| Exact Sciences Corporation | $309.14 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $283.69 | 2020-2024 | Xarelto |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Orendorff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.